| Variable |
|
BF |
|
|
|
| |
|
Number |
BF |
% |
p |
| Race |
Yellow |
17 |
1 |
5,9 |
<0.001 |
| |
White |
181 |
49 |
27,1 |
|
| |
Black |
18 |
10 |
55,6 |
|
| |
Brown |
13 |
5 |
38,5 |
|
| |
|
|
|
|
|
| CS |
< 2b |
160 |
35 |
21,9 |
0.004 |
| |
≥ 2b |
69 |
30 |
43,5 |
|
| |
|
|
|
|
|
| Neoadj HT |
Yes |
107 |
25 |
23,4 |
0.152 |
| |
No |
122 |
40 |
32,8 |
|
| |
|
|
|
|
|
| Adj HT |
Yes |
173 |
50 |
28,9 |
|
| |
No |
56 |
15 |
26,8 |
|
| |
|
|
|
|
|
| Risk Group |
Intermediate |
122 |
25 |
20,5 |
0.055 |
| |
High |
107 |
40 |
37,4 |
|
| |
|
|
|
|
|
| HDR Dose (Gy) |
< 20 |
85 |
45 |
52,9 |
<0.001 |
| |
20-24 |
144 |
20 |
13,9 |
|
| |
|
|
|
|
|
| iPSA |
<10 |
56 |
20 |
35,7 |
0.225 |
| |
10-20 |
105 |
25 |
23,8 |
|
| |
>20 |
68 |
20 |
29,4 |
|
| |
|
|
|
|
|
| GS |
<7 |
146 |
36 |
24,7 |
0.001 |
| |
7 |
56 |
18 |
32,1 |
|
| |
>7 |
27 |
11 |
40,7 |
|
| GS – reference 7 |
≤ 7 |
202 |
54 |
26,7 |
0.009 |
| |
>7 |
27 |
11 |
40,7 |
|
| |
|
|
|
|
|
| EBRT |
<50 |
125 |
39 |
31.2 |
|
| |
≥ 50 |
104
|
26 |
25.0 |
0.060 |
| |
|
|
|
|
|
| Age |
≥ 65 |
75 |
25 |
33.3 |
0.094 |
| |
>65 |
154 |
40 |
26.0 |
|
iPSA: Initial PSA Value; GS: Geason Score; IR: Intermediate Risk; HR: High Risk;
neoadj HT: Neoadjuvant Androgen Deprivation; adj HT: Neoadjuvant Androgen
Deprivation; EBRT: External Beam Radiotherapy; HDR-BT: High Dose Rate
Brachytherapy |
